Ascendis Pharma A/S (ASND) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET

Company Participants

Tim Lee - Senior Director, Investor Relations

Jan Mikkelsen - President and Chief Executive Officer

Scott Smith - Senior Vice President and Chief Financial Officer

Dana Pizzuti - Head, Development Operations and Chief Medical Officer

Stina Singel - Head, Clinical Development Oncology

Joe Kelly - Head, U.S. Commercial Endocrinology

Conference Call Participants

Jessica Fye - JPMorgan

Josh Schimmer - Evercore

Tazeen Ahmad - Bank of America

David Lebowitz - Citibank

Li Watsek - Cantor

Vikram Purohit - Morgan Stanley

Operator

Good day and thank you for standing by. Welcome to the Ascendis Pharma Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your first speaker for today, Mr. Tim Lee, Senior Director of Investor Relations for Ascendis Pharma. Please go ahead.

Tim Lee

Thank you, operator and thank you everyone for joining our second quarter 2022 financial results conference call today. I am Tim Lee, Senior Director of Investor Relations of Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Senior Vice President and Chief Financial Officer; Dr. Dana Pizzuti, Head of Development Operations and Chief Medical Officer; Dr. Stina Singel, Head of Clinical Development Oncology; and Joe Kelly, Head of U.S. Commercial Endocrinology.

Before we begin, I would like to remind you that this conference call will include forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to our U.S. commercialization and continued development of SKYTROFA for the U.S. market. the U.S. – excuse me, the commercialization of TransCon hGH for the EU market, our progress on our pipeline candidates and our expectations with respect to their continued progress, statements regarding our strategic plans, our goals regarding our clinical pipeline, including the timing of clinical results, statements regarding the U.S. market approval of SKYTROFA and our product pipeline candidates, statements regarding our planned filings, our extension – our expansion into the new therapeutic areas and statements regarding our ability to create a sustainable leading global biopharma company. These statements are based on information that is available to us today.

Actual results and events could differ materially for those in the forward-looking statements and we may not be able to achieve our goals, carry out our plans or intentions or expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these statements. Our forward-looking statements do not reflect the potential impact of any licensing agreements, acquisitions, mergers, dispositions, joint ventures or investments that we may enter into or terminate. We assume no obligation to update these statements as circumstances change, except as required by law. For additional information concerning the factors that cause actual results to differ materially, please see our forward-looking statements section in today’s press release and the Risk Factors section of our most recent annual report on Form 20-F filed with the SEC on March 2, 2022.